Amycretin
Novo Nordisk\'s Dual GLP-1 + Amylin Agonist
Amycretin is Novo Nordisk\'s investigational dual GLP-1 and amylin receptor agonist. Unlike single-mechanism GLP-1 drugs, amycretin simultaneously activates both the GLP-1 and amylin pathways, combining appetite suppression from two different hormonal systems. In Phase 1b/2a trials, the subcutaneous form showed 22% weight loss at the highest dose over just 36 weeks, with an oral formulation also in development. Use the Shotlee app to track your current protocol and build baseline data for whatever comes next.
What Is Amycretin?
Amycretin is Novo Nordisk\'s investigational dual GLP-1 and amylin receptor agonist. Unlike single-mechanism GLP-1 drugs, amycretin simultaneously activates both the GLP-1 and amylin pathways, combining appetite suppression from two different hormonal systems. In Phase 1b/2a trials, the subcutaneous form showed 22% weight loss at the highest dose over just 36 weeks, with an oral formulation also in development.
Track your current protocol in Shotlee while this science evolves. Having clean historical data means you can compare outcomes with precision if you ever switch medications.
How It Works
GLP-1 Agonism
Amylin Agonism
- • Promotes satiety signaling
- • Controls gastric emptying
- • Suppresses post-meal glucagon
- • Complementary to GLP-1
Dual Synergy
- • Two pathways working together
- • Potentially superior weight loss
- • Available as oral AND injectable
- • Track dual-agonist results in Shotlee
Why This Matters
By combining GLP-1 and amylin signaling in a single molecule, amycretin attacks appetite and metabolism from two angles simultaneously. The oral formulation showing 13% weight loss in just 12 weeks is particularly exciting for patients who prefer pills over injections.
Clinical Data
Subcutaneous highest dose showed 22% mean weight loss over 36 weeks with no plateau observed.
Oral formulation achieved 13% weight loss in only 12 weeks in Phase 1 — an unusually rapid result.
In Phase 2 for Type 2 diabetes, subcutaneous amycretin showed 14.5% weight loss at 36 weeks.
Side Effects
- • Nausea (mild to moderate)
- • GI symptoms consistent with GLP-1 class
- • Generally well tolerated
- • No major safety signals
Vital Protocol FAQs
Is Amycretin a GLP-1 or amylin drug?
It is both. Amycretin is a dual GLP-1 and amylin receptor agonist, meaning it activates two different hormone pathways simultaneously. This makes it mechanistically distinct from pure GLP-1 drugs like Semaglutide. Track your protocol in the Shotlee app.
Can I get Amycretin now?
No, Amycretin is still investigational. Phase 3 trials are expected to begin in Q1 2026. Use Shotlee to track your current protocol and build baseline data.
Will there be an oral version?
Yes, Novo Nordisk is developing both subcutaneous and oral formulations. The oral version showed 13% weight loss in just 12 weeks in Phase 1. Track your progress in Shotlee regardless of formulation.
Prepare for Better Protocol Outcomes
Track your protocol with Shotlee and make every decision from clean, visible data instead of guesswork.
🚀 Use Shotlee for Free